Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Current guidelines in defining therapeutic strategies.

Alessandra Ferrajoli1, Michael J Keating

  • 1Department of Leukemia, The University of Texas, M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Box 428, Houston, TX 77030, USA. aferrajoli@mdanderson.org

Hematology/Oncology Clinics of North America
|August 25, 2004
PubMed
Summary

Chronic lymphocytic leukemia (CLL) treatment has evolved significantly over 30 years. Modern approaches now focus on complex disease management with targeted therapies and monitoring minimal residual disease.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Adjunct Hyperbaric Oxygen Therapy for Refractory Infections in Patients with Hematologic Malignancies: A Single-Center Retrospective Study.

Cancers·2026
Same author

Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial.

Lancet (London, England)·2026
Same author

Standardizing the Clinical Approach to Cancer Therapy-Related Cardiac Dysfunction: Applying Cardio-Oncology Guidelines as a Practical Tool for Hematology and Oncology Providers.

Cancer medicine·2026
Same author

NGS-based measurable residual disease in long-term progression-free CLL survivors following FCR therapy.

Blood advances·2026
Same author

Is CLL curable?

HemaSphere·2026
Same author

Clinical, genetic, and familial features of POT1 tumor predisposition syndrome.

Cancer·2026

Area of Science:

  • Hematology
  • Oncology
  • Immunology

Background:

  • Chronic lymphocytic leukemia (CLL) was historically viewed as a simple leukemia manageable by controlling leukocytosis and symptoms.
  • Recent decades have seen major advancements in understanding CLL biology and identifying prognostic markers.

Purpose of the Study:

  • To review the evolution of chronic lymphocytic leukemia (CLL) management.
  • To highlight the shift towards a more complex understanding and treatment of CLL.

Main Methods:

  • Literature review of advancements in CLL research and clinical practice over the past three decades.
  • Analysis of emerging treatment modalities and diagnostic evaluations.

Main Results:

  • CLL is now recognized as a complex leukemia requiring diverse treatment strategies.

Related Experiment Videos

  • New prognostic markers are integrated into clinical practice.
  • Treatment evaluation now includes monitoring genetic aberrations and minimal residual disease.

    • Conclusions:

    • The approach to chronic lymphocytic leukemia (CLL) has transformed from symptom management to complex, personalized treatment.
    • Advances in biology, prognostics, and treatment evaluation have revolutionized CLL care.